*******
Opioides de liberación retardada
La definición más aceptada del dolor es la propuesta por la Asociación Internacional para el Estudio del Dolor (Internacional Association for the Study of Pain): el dolor es una experiencia sensorial y emocional no placentera relacionada con daño potencial o real del tejido, o descrita en términos de dicho daño.
Autor/a: Luis Miguel Torres Moreira, jefe del Servicio de Anestesia, María Vidal, al Servicio de Anestesia
Indice
1. Referencias bibliográficas
2. Introducción
3. Liberación sostenida de opioides
4. Fentanilo.
5. Buprenorfina. Conclusiones
2. Coluzzi F, Papagayo M. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol 2005;71:425-433.
3. Chevlen E. Opioids: a review. Curr Pain Headache Rep 2003;7:15-23.
4. Pasternak GW. Opioid pharmacology. In: Papagayo M, editor. The neurological basis of pain. New Cork: McGray Hill 2004, p. 61-70.
5. Rowbotham MC, Twilling L, Davies PS, et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003;348:1223-1232.
6. Moulin DE, Lezzi A, Amireh Z, et al. Randomised trial of oral morphine for chronic non-cancer pain. Lancet 1996;347:143-147.
7. Volles DF, McGory R. Pharmacokinetic Considerations. Crit Care Clin 1999, 15:55-75.
8. Markenson JA, Croft J, Zhang PG, et al. Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain. 2005 nov-dec;21(6):524-535.
9. Zautra AJ, Smith BW. Impact of controlled-release oxycodone on efficacy beliefs and coping efforts among osteoarthritis patients with moderate to severe pain. Clin J Pain. 2005 nov-dec;21(6):471-477.
10 De Beer Jde V, Winemaker MJ, Donnelly GA, et al. Efficacy and safety of controlled-release oxycodone and standard therapies for postoperative pain after knee or hip replacement. Can J Surg. 2005 aug;48(4):277-283.
11. Kalso E. Oxycodone. J Pain Symptom Manage. 2005 May;29(5 Suppl):S47-56.
12. Kokki H, Lintula H, Vanamo K, et al. Oxycodone vs placebo in children with undifferentiated abdominal pain: a randomized, double-blind clinical trial of the effect of analgesia on diagnostic accuracy. Arch Pediatr Adolesc Med. 2005 apr;159(4):320-325.
13. Lugo RA, Kern SE. The pharmacokinetics of oxycodone. J Pain Palliat Care Pharmacother. 2004;18(4):17-30.
14. Mystakidou K, Katsouda E, Tsilika E, et al. Transdermal therapeutic fentanylsystem (TTS-F). In Vivo 2004 sep-oct;18(5):633-642.
15. Libretto SE. Use of transdermal fentanyl in patients with continuous nonmalignant pain. Clin Drug Invest 2002;22:473-483.
16. Komick CA. Benefi-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Safety 2003:26:951-973.
17. Broome IJ, Wright BM, Bower S, et al. Postoperative analgesia with transdermal fentanyl following lower abdominal surgery. Anaesthesia 1995; 50:300-303.
18. Simpson RL, Edmonson EA, Constant CF, et al. Transdermal Fentayl as treatment for chronic low back pain. Journal Pain Symptom Management 1997; 14:218-224.
19. Estève M. Pharmacologie des morphiniques: Voies orale et transdermique MED THER 1995: 659-667. Estève M. Pharmacologie des morphiniques: Voies orale et transdermique MED THER 1995: 659-667.